Developing A High-Throughput Formulation Development Platform For High-Concentration, Therapeutic Monoclonal Antibodies

Some of the challenges in early stages of a pharmaceutical are a limited supply of protein to use in formulation screening studies, and a need to obtain stability data quickly to initiate tox studies. In this poster, scientists at Catalent Biologics outline a method utilizing a high-throughput, micro-well plate platform to economically screen a mAb in 96 formulations.

Click here to download poster.